Nurix Therapeutics Falls After Partner Sanofi Halts Oral STAT6 Degrader
Sanofi has terminated the SAR448272 STAT6 degrader program. Nurix shares fell sharply in after-hours trading, but cash runway remains intact through 2029.
Sanofi has terminated the SAR448272 STAT6 degrader program. Nurix shares fell sharply in after-hours trading, but cash runway remains intact through 2029.
Under new CEO Garijo, Sanofi says it may pursue larger acquisitions while lifting 2026 growth targets after strong Dupixent-led Q3 results.
Revenue grew 36% and non-GAAP EPS rose 70% on record Dupixent and EYLEA HD sales.
Amgen and AstraZeneca’s Tezspire showed high histologic remission and symptom improvement in Phase 3 EoE trial, positioning it as a potential Dupixent rival.
MacroGenics receives $24.5 million from Sanofi after FDA expands TZIELD approval to children aged 8-17 with newly diagnosed stage 3 Type 1 diabetes.
Raymond James reiterated its Strong Buy rating and $125 price target on Dianthus after the company reported strong early data from the Phase 3 CAPTIVATE study of claseprubart in CIDP.